Hemab Secures $157m in Funding for Bleeding Disorder Treatments
Hemab Therapeutics has successfully completed an oversubscribed Series C funding round, raising $157m to further develop therapies for bleeding disorders.
Following the completion of a Phase II trial of sutacimig, Hemab is preparing to progress to a registration trial in 2026.
- The investment round was led by Sofinnova Partners.
- A global asset management company and new investors, including a sovereign wealth fund and Avoro Capital Advisors, contributed to the round.
- Existing stakeholders, such as Access Biotechnology, Avoro Ventures, Deep Track Capital, Invus, Maj Invest Equity, Novo Holdings, RA Capital Management, and Rock Springs Capital, continued their support.
As a result of this funding, Sofinnova partner Joe Anderson will join the Hemab board.
No direct quote available in the text.
Author's summary: Hemab raises $157m for bleeding disorder treatments.
More News
- Hemab closes $157m in funding for bleeding disorder treatments
- Giving States Waivers From Accountability Is a Dangerous Step Backward for Kids
- Officials Plan to Set Fire to Vegetation Around Lake Tahoe This Week — and They Have a Good Reason
- Industrial profits post fast growth-Dahe.cn - The first brand of local news website in Henan.
- Most of the world’s space launches are controlled by just three countries
- Quantum Threats Demand Post-Quantum Cryptography Now
- Cisco and G42 Deepen US-UAE Technology Partnership to Build Secure, End-to-End AI Infrastructure in the UAE
- Schenectady launches school zone camera demonstration program
- Suspect in Charlie Kirk killing can wear street clothes in court amid ‘extraordinary’ attention | Fulton Sun
- Liverpool decline Slot press conference before Palace cup tie